cardurion.comHealthcare / Healthcare softwareFounded: 2017Funding to Date: $866.77MM
Cardurion Pharmaceuticals is a biotechnology company that specializes in the discovery and development of therapies intended for cardiovascular disease. Cardurion Pharmaceuticals was founded in 2017 and is headquartered in Burlington, MA. Striving to address the unique needs of patients suffering from heart disease through novel approaches, the team manages the development and clinical trial stages for patients suffering from chronic heart failure along with related therapies that have broad potential for cardiovascular disease treatment.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/16/2024 | Series B | $260.41MM | $xx.xx | $754.94MM | Ascenta Capital, Bain Capital Life Sciences, Bain Capital Private Equity, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures, Farallon Capital Management, Fidelity Management & Research Company, Gv, Invus, Millennium Management, Nea | |
Price per Share
$xx.xx
Shares Outstanding
53,171,088
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ascenta Capital, Bain Capital Life Sciences, Bain Capital Private Equity, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures, Farallon Capital Management, Fidelity Management & Research Company, Gv, Invus, Millennium Management, Nea
|
||||||
07/14/2023 | Series A-5 | $47.5MM | $xx.xx | $508.61MM | Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals | |
Price per Share
$xx.xx
Shares Outstanding
12,101,294
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
|
||||||
10/27/2021 | Series A-4 | $31.38MM | $xx.xx | $425.28MM | Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals | |
Price per Share
$xx.xx
Shares Outstanding
9,404,601
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
|
||||||
10/27/2021 | Series A-3 | $99.97MM | $xx.xx | $425.28MM | Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals | |
Price per Share
$xx.xx
Shares Outstanding
25,468,730
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
|
||||||
11/20/2019 | Series A-1 | $46.12MM | $xx.xx | $157.83MM | Polaris Partners | |
Price per Share
$xx.xx
Shares Outstanding
14,101,191
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Polaris Partners
|
||||||
03/20/2017 | Series A-2 | $14.46MM | $xx.xx | $72.28MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
5,198,934
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|